Processa Pharmaceuticals (PCSA) investor relations material

Executive summary

• Clinical-stage biopharma focused on Next Generation Cancer (NGC) therapies, with two oncology candidates (NGC-Cap and NGC-Iri) and two non-oncology assets in development or out-licensing discussions.

• NGC-Cap (PCS6422 + capecitabine) in Phase 2 for metastatic breast cancer; interim analysis expected H1 2026.

• NGC-Iri (PCS11T) in preclinical development, targeting improved tumor selectivity and safety over irinotecan.

• No product revenue; operations funded by equity offerings and a digital asset treasury strategy.

Financial highlights

• Net loss for 2025 was $13.6 million, up from $11.9 million in 2024, driven by increased R&D and G&A expenses.

• Research and development expenses rose to $7.8 million in 2025, primarily due to clinical trial activity.

• General and administrative expenses increased to $6.2 million, reflecting higher payroll, stock compensation, and professional fees.

• No revenue recognized in 2025 or 2024.

• Cash and cash equivalents at year-end 2025 were $5.5 million; digital assets (CHZ tokens) valued at $1.1 million.

• Accumulated deficit reached $100.8 million as of December 31, 2025.

Outlook and guidance

• Management expects continued operating losses and negative cash flows; additional capital needed by Q2 2026 to fund operations and clinical programs.

• Plans to raise capital through equity, debt, or strategic transactions; failure to secure funding may delay or halt development programs.

• Focus remains on advancing NGC-Cap through Phase 2 and progressing NGC-Iri preclinical work, subject to financing.